Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study

被引：9
|
作者：
Luebbert, Michael [1 ]
Rueter, Bjorn [1 ]
Claus, Rainer
Schmid, Mathias [2 ]
Germing, Ulrich [3 ]
Eimeracher, Hartmut [4 ]
Ganser, Arnold [5 ]
Platzbecker, Uwe [6 ]
Galm, Oliver [7 ]
Brugger, Wolfram [8 ]
Heil, Gerhard [9 ]
Wijermans, Pierre W. [10 ]
Pfeifer, Dietmar [1 ]
Schmoor, Claudia [11 ]
Doehner, Hartmut [2 ]
机构：
[1] Univ Hosp, Freiburg, Germany
[2] Univ Hosp, Ulm, Germany
[3] Univ Hosp, Dusseldorf, Germany
[4] Catholic Hosp, Hagen, Germany
[5] Univ Hosp, Hannover, Germany
[6] Univ Hosp, Dresden, Germany
[7] Univ Hosp, Aachen, Germany
[8] Hospital, Villigen Schwenningen, Germany
[9] Hospital, Ludenscheid, Germany
[10] Leyenburg Hosp, The Hague, Netherlands
[11] Univ Hosp, Ctr Clin Trials, Freiburg, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.300.300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：95A / 95A
页数：1
相关论文
共 50 条
  • [21] Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
    Kim, Young Saing
    Sym, Sun Jin
    Baek, Min Young
    Park, Inkeun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Jinny
    Cho, Eun Kyung
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1267 - 1272
  • [22] A PILOT STUDY OF LOW-DOSE CAPECITABINE PLUS TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS AGED 75 YEARS OR OLDER WITH HER2-POSITIVE ADVANCED GASTRIC CANCER
    Kim, Y. S.
    Sym, S. J.
    Park, I.
    Hong, J.
    Ahn, H. K.
    Park, J.
    Cho, E. K.
    Lee, W. K.
    Chung, M.
    Kim, H. S.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E18 - E18
  • [23] A PILOT STUDY OF LOW-DOSE CAPECITABINE PLUS TRASTUZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS OLDER THAN 75 YEARS WITH HER2-POSITIVE ADVANCED GASTRIC CANCER
    Sym, S. J.
    Kim, Y. S.
    Park, I.
    Ahn, H. K.
    Hong, J.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Lee, W. K.
    Chung, M.
    Kim, H. -S.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E67 - E67
  • [24] Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
    Hund, Inga
    Hess, Maria
    Stomper, Julia
    Greve, Gabriele
    Mitschke, Jan
    Niemoeller, Christoph
    Ma, Tobias
    Uhl, David
    Thol, Felicitas R.
    Heuser, Michael
    Bug, Gesine
    Crysandt, Martina
    Mueller, Lutz Peter
    Neubauer, Andreas
    Duyster, Justus
    Dohner, Hartmut
    Boerries, Melanie
    Becker, Heiko
    Luebbert, Michael
    BLOOD, 2022, 140 : 3383 - 3384
  • [25] Phase II study of low-dose methotrexate to reduce the incidence of human anti-mouse antibodies in patients receiving I-131 tositumomab as first-line treatment for follicular lymphoma.
    Lebovic, Daniel
    Avram, Anca M.
    Dewaraja, Yuni
    Estes, Judith
    Jacobi, Kathryn
    Goeman, Sara
    Kyle, Sarah
    Chapman, Erica
    Griffith, Kent A.
    Kaminski, Mark Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Shen, Ying-Chun
    Li, Chung-Pin
    Yen, Chia-Jui
    Hsu, Chiun
    Lin, Yu-Lin
    Lin, Zhong-Zhe
    Chen, Li-Tzong
    Su, Wu-Chou
    Chao, Yee
    Yeh, Kun-Huei
    Cheng, Ann-Lii
    ONCOLOGY, 2014, 87 (02) : 104 - 113
  • [27] Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers
    Yeh, K.
    Shen, Y.
    Li, C.
    Yen, C.
    Hsu, C.
    Lin, Z.
    Chen, L.
    Su, W.
    Chao, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [28] A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment for patients older than 75 years with HER2-positive advanced gastric cancer.
    Sym, Sun Jin
    Kim, Young Saing
    Park, Inkeun
    Ahn, Hee Kyung
    Hong, Junshik
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Shin, Dong Bok
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] A multicenter randomized phase II trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study
    Bando, Hideaki
    Satake, Hironaga
    Kotani, Daisuke
    Hamaguchi, Tetsuya
    Shiozawa, Manabu
    Ikumoto, Taro
    Okita, Yoshihiro
    Masuishi, Toshiki
    Kagawa, Yoshinori
    Yasui, Hisateru
    Oki, Eiji
    Komatsu, Yoshito
    Taniguchi, Hiroya
    Muro, Kei
    Kotaka, Masahito
    Yamazaki, Kentaro
    Misumi, Toshihiro
    Yoshino, Takayuki
    Kato, Takeshi
    Tsuji, Akihito
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer:: Results of a phase II study
    Firvida, JL
    Amenedo, M
    Rodríguez, R
    González, A
    Salgado, M
    Ramos, M
    Losada, G
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) : 481 - 487
12345